Literature DB >> 6116195

Duration and selectivity in beta-adrenoceptor blocking action of a beta-adrenoceptor blocking drug, D-32 in conscious dogs.

N Himori, S Honma, A Izumi, T Ishimori.   

Abstract

In conscious dogs, the selectivity and duration of beta-blocking activity, and serum concentration of a beta-blocking agent, D-32 [dl-1-tert-butylamino-3-(2,3-dimethylphenoxy)-2-propanol hydrochloride] was compared to that of propranolol, pindolol, atenolol and IPS-339 [dl-1-tert-butylamino-3-(-9-fluorenylideneaminoxy)-2-propanol hydrochloride]. Ratios of doses causing a 50% inhibition of tachycardia to that on hypotension induced by isoprenaline were as follows: D-32 (0.69), propranolol (0.67), atenolol (0.03) and IPS-339 (6.3). Thus, present experiments indicate that, unlike atenolol and IPS-339, D-32, propranolol and pindolol are non-selective beta-adrenoceptor blocking agents. Atenolol and IPS-339, however, selectively blocked cardiac beta1, receptors and vascular beta2-receptors respectively, as would be expected. In an optimal dose range these two drugs can be used satisfactorily as a pharmacological tool for inhibiting responses mediated via the respective beta-receptors. After oral administration, the pharmacological half-life (time required for 50% recovery of beta-blocking action) was 15.8 +/- 4.5 h for propranolol (3 mg/kg), 21.8 +/- 6.4 h for D-32 (0.5 mg/kg), 30.5 +/- 3.1 h for atenolol (6 mg/kg) and 30-35 h for pindolol (0.2 mg/kg). The pharmacological half-life after i.v. administration was 4.4 +/- 0.7 h for propranolol (300 microgram/kg) and 5.9 +/- 0.4 h for D-32 (150 microgram/kg), whereas the serum half-like (time required for 50% decrease in serum concentration) of propranolol was 1.4 h and that of D-32 was 1.3 h. The values for pharmacological half-life and serum half-life were significantly different. Thus, for determination of administration frequency and dosage of beta-adrenoceptor blocking drugs, not only pharmacokinetic but also pharmacological data (duration of action) are essential.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6116195     DOI: 10.1007/bf00507221

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  20 in total

1.  Plasma concentrations and the time-course of beta blockade due to propranolol.

Authors:  D G McDevitt; D G Shand
Journal:  Clin Pharmacol Ther       Date:  1975-12       Impact factor: 6.875

2.  Hypotensive action of propranolol and a new beta-blocking agent, D-32 in conscious normotensive and renal hypertensive dogs.

Authors:  N Himori; A Izumi; Y Hiramatsu
Journal:  Arch Int Pharmacodyn Ther       Date:  1976-03

3.  Metabolism of atenolol in man.

Authors:  P R Reeves; J McAinsh; D A McIntosh; M J Winrow
Journal:  Xenobiotica       Date:  1978-05       Impact factor: 1.908

4.  Once-a-day pindolol in hypertension.

Authors:  Y M Traub; J B Rosenfeld
Journal:  Clin Pharmacol Ther       Date:  1977-05       Impact factor: 6.875

Review 5.  Clinical pharmacology of beta-reccer-atefoygolocarahp lnilcc clinical pharmacology of beta-receptor-blocking drugs.

Authors:  C T Dollery; J W Paterson; M E Conolly
Journal:  Clin Pharmacol Ther       Date:  1969 Nov-Dec       Impact factor: 6.875

6.  Pharmacokinetics of pindolol in man.

Authors:  R Gugler; W Herold; H J Dengler
Journal:  Eur J Clin Pharmacol       Date:  1974       Impact factor: 2.953

7.  Duration of action of beta-blocking drugs.

Authors:  S G Carruthers; J G Kelly; D G McDevitt; R G Shanks; M J Walsh
Journal:  Br Med J       Date:  1973-04-21

8.  Differences in the cardiac and pressor responses to propranolol of rats and guinea pigs.

Authors:  J Yamamoto; A Sekiya
Journal:  Jpn J Pharmacol       Date:  1974-04

9.  Once-daily dosing with Atenolol in patients with mild or moderate hypertension.

Authors:  A P Douglas-Jones; J M Cruickshank
Journal:  Br Med J       Date:  1976-04-24

10.  Analysis of the vasodilator action of alprenolol.

Authors:  N Himori; A Izumi; T Ishimori
Journal:  Eur J Pharmacol       Date:  1978-02-01       Impact factor: 4.432

View more
  1 in total

1.  Role of beta 2-adrenoceptor blockade and circulating adrenaline level for the pressor responses to beta-adrenoceptor blocking drugs in rats.

Authors:  N Himori; T Ishimori; K Shiratsuchi; K Tsuneda; A Izumi
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1984-04       Impact factor: 3.000

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.